|
Prostate Cancer Research Foundation announces over £600,000 for new research projects
The Prostate Cancer Research Foundation (PCRF) has announced funding of over £600,000 to support seven research projects to assist in finding a cure for prostate cancer. The funding, announced on Friday 10 February 2006, brings the total number of PCRF funded research projects to 23 since 1998 totaling over one million pounds.
Sir Clive Bourne, Chairman of the PCRF, said: "We are very excited to be funding these cutting edge research projects into a disease that kills one man every hour in the UK. It is only through funding more research that we will eventually have a better understanding of prostate cancer, and ultimately be able to discover the cures."
Previous research funded by the PCRF at the Institute of Cancer Research has provided evidence that differences in the genetic make-up of men’s immune systems can have a direct bearing on their chances of developing prostate cancer.
The successful projects to receive PCRF funding are
| Project Title |
Researcher |
Institution |
Amount of support |
| Development and assessment of targeted radionuclide combined with death inducing and growth inhibiting immunotherapy for potential treatment of hormone refractory prostate cancer (HRPC) |
Dr Ahuva Nissim & Professor Stephen J Mather |
Barts and the London School of Medicine |
£46,000 per year for two years |
| |
|
|
|
| Isolation, culture and molecular characterisation of castration-refractory prostate cancer (CRPC) stem cells from clinical tumour material |
Dr Johann de Bono, Dr Siân Rizzo and Dr David Hudson |
Prostate Stem Cell Laboratory, Institute of Cancer Research, Sutton |
£33,000 per year for three years |
| |
|
|
|
| Importance of Interleuken-8 signalling as a mode of resistance of prostate cancer cells to ionizing radiation |
Dr David Waugh, PhD |
Centre for Cancer Research and Cell Biology, Queen's University, Belfast |
£27,000 per year for three years |
| |
|
|
|
| Endogenous anti-angiogenic tumour supporessing VEGF splice variants in the treatment of prostate cancer |
Dr Steven Harper, Mr David Gillatt and Dr Dave Bates |
Bristol Urological Institute |
£41,000 per year for two years |
| |
|
|
|
| A gene therapy strategy for metastatic prostate cancer: use of a novel molecular switch for transcriptional tageting of iNOS |
Prof David Hurst, Dr Tracy Robson and Dr Helen McCarthy |
School of Pharmacy, Queen's University, Belfast |
£46,000 for one year |
| |
|
|
|
| Development of oncolytic adenoviruses for targeting of androgen-independent prostate cancers: enhancement of anti-tumour efficacy by combination therapies |
Dr Gunnel Halldén |
Cancer Research UK, Barts and the London School of Medicine and Dentistry |
£32,000 per year for three years |
| |
|
|
|
| Investigation of environmental, lifestyle and genetic risk factors for prostate cancer in younger men |
Prof Kenneth Muir |
University of Nottingham Medical School |
£34,000 per year for three years |
| |
|
|
|
:
|
News 
